Sertraline

Sertraline is an orally active antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) family. Chemically it is a naphthalenamine (1-aminotetralin) derivative, and it is usually supplied as the hydrochloride salt in tablet and oral concentrate forms ^[4]. The molecule was first synthesized by Pfizer chemists during the 1970s in a program exploring compounds related to earlier neuroleptic agents, and it reached the United States market in 1991 ^[1].

Regulatory approvals span major depressive disorder as well as obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder; it is also used off-label for conditions such as premature ejaculation ^[4]. A large network meta-analysis comparing 21 antidepressants placed sertraline among the agents with a favorable balance of efficacy and acceptability, which has helped make it a common first-line choice ^[1]. Evidence also supports its value for relapse prevention during longer maintenance treatment, although tolerability during extended use varies between people ^[2].

Sertraline is absorbed slowly after oral dosing and undergoes extensive first-pass metabolism to N-desmethylsertraline, a weakly active metabolite ^[4]. Its elimination half-life supports once-daily administration, and it has comparatively modest effects on the major cytochrome P450 enzymes, so clinically important drug interactions are relatively uncommon ^[4]. Inherited variation in enzymes such as CYP2C19 and CYP2D6 can influence how quickly a given person clears the drug, and pharmacogenetic guidelines describe how such differences may inform prescribing ^[3].

The drug is a prescription-only medicine in the United States, United Kingdom, Canada, and Australia, and generic versions have been available since the mid-2000s ^[1]. Like other SSRIs it carries class-wide cautions, including heightened attention to suicidal thinking in younger patients, and stopping it abruptly can trigger discontinuation symptoms ^[3]. Overall it is regarded as well tolerated and relatively safe in overdose compared with older tricyclic antidepressants ^[4].

Sertraline is a widely used SSRI whose common effects include nausea, diarrhea, insomnia, and sexual dysfunction. It carries a boxed warning for increased suicidal thoughts in children, adolescents, and young adults, and can rarely cause serotonin syndrome (especially when combined with other serotonergic drugs), low sodium (hyponatremia), and increased bleeding risk, particularly with NSAIDs or anticoagulants. Abrupt discontinuation can cause withdrawal symptoms, so it should be tapered under medical supervision and not combined with MAO inhibitors.

Sertraline is a CYP2D6 inhibitor that reduces the metabolism of opioid analgesics, particularly affecting drugs like hydrocodone that rely on CYP2D6 for conversion to active metabolites. In a large cohort study of patients initiating an SSRI while on hydrocodone, sertraline showed the lowest risk profile among SSRIs for opioid overdose events, whereas other SSRIs (citalopram, escitalopram, fluoxetine, paroxetine) that are stronger CYP2D6 inhibitors increased overdose risk by 17-29 percent; this is a pharmacokinetic interaction where sertraline changes opioid metabolism ^[23]. Sertraline also affects esketamine pharmacokinetics when given as adjunctive therapy; patients on sertraline showed lower serum esketamine levels compared to those on paroxetine or fluoxetine, again reflecting its relatively mild CYP inhibition ^[24]. The interaction with most tramadol-type opioids remains documented but sertraline carries less risk than other SSRIs in this class.

Sertraline's clinical significance is mainly limited to opioid pain medications and NMDA antagonist anesthetics. There is minimal documented interaction risk with most other drug classes. The absence of data means combinations with antihistamines, stimulants, anticholinergics, and most supplements are not formally studied and remain unknown.

Checking a whole stack? Run it through interactions + stacks.

Sertraline was discovered by chemists at Pfizer, where Kenneth Koe, Willard Welch, and Reinhard Sarges worked from a series of compounds related to the earlier molecule tametraline to arrive at a potent and selective serotonin reuptake inhibitor. Synthesized in the early 1980s, it was developed through clinical trials over the following years and approved by the United States Food and Drug Administration in 1991. Marketed most widely under the brand name Zoloft, it went on to become one of the most frequently prescribed antidepressants of its class. Beyond major depression, it earned approvals across a notably broad set of anxiety-spectrum conditions, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder.

Sertraline is one of the most widely prescribed and clinically respected antidepressants, often chosen as a sensible first-line option. In a landmark network meta-analysis of twenty-one antidepressants, it was repeatedly highlighted as offering one of the better balances of efficacy and acceptability, which has reinforced its standing among prescribers. Its unusually broad range of approved uses, spanning depression and several anxiety and stress-related disorders, adds to its versatility. Patients and clinicians benefit from decades of accumulated experience with the drug. As with all medicines in this class, it has trade-offs, including the potential for sexual side effects, gastrointestinal upset, and discontinuation symptoms, and full benefit typically emerges over several weeks. On the whole it is regarded as an effective and dependable choice.